Abstract 937
Background
The prognosis of type 4 or large type 3-gastric cancer is extremely poor. Despite various perioperative adjuvant therapies; as JCOG0501, peritoneal recurrence is still difficult to control. Since the clinical efficacy of chemo-radiotherapy was suggested for the treatment of advanced gastric cancer, chemo-radiotherapy is a promising strategy for curatively resectable type 4 or large type 3-gastric cancer. This multicenter, phase II study evaluated the efficacy and safety of radiotherapy combined with S-1 plus cisplatin for this target.
Methods
Eligibility criteria included pathologically confirmed gastric adenocarcinoma with macroscopically type 4 or large type 3, without peritoneal or distant metastases. Patients received preoperative chemo-radiotherapy with S-1 80 mg/m2/day from Day 1 to 14 and cisplatin 60 mg/m2 on Day 1, and radiotherapy at a total dose of 40 Gy in 20 fractions was delivered for 4 weeks, followed by D2 gastrectomy, and received S-1 monotherapy for one year postoperatively. The primary endpoint was the pathological complete response rate (% protocol completion). Secondary endpoints were safety, overall survival, and the response rate (RR). The sample size was calculated to be 30 cases, under the hypothesis of expected % pathological complete response rate of 15% and threshold pathological complete response rate of 2% with one-sided testing at the 10% significance level and power of 90%.
Results
From November 2012 to April 2018, 20 patients were enrolled. A median age of 20 patients was 67 years. Nineteen patients had protocol operation, and two of them showed pathological complete response (10.5%; 95% confidence interval 1.3–33.1%, p < 0.001). During preoperative chemotherapy, grade 3/4 neutropenia occurred in 25%, and grade 3/4 non-hematological adverse events occurred in 10%. The incidence of adverse events related to surgery was occurred in 31.6% patients. There were no treatment-related deaths. Follow-up for long-term survival is continuing. Notably the pathological RR (residual tumor < 2/3) was 100% (19/19).
Conclusions
Preoperative chemo-radiotherapy with S-1 plus CDDP is a safe and promising treatment for type 4 or large type 3 gastric cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Osaka Gastointestinal Cancer Chemotherapy Study Group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
733 - Clinical experience: ramucirumab with FOLFIRI/XELIRI as a second line for patients with metastatic gastric cancer
Presenter: Tatiana Titova
Session: Poster Display session 2
Resources:
Abstract
2186 - Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
Presenter: Ningning Li
Session: Poster Display session 2
Resources:
Abstract
3172 - Apatinib in combination with docetaxol and S1 chemotherapy in the first line treatment of metastatic gastric cancer
Presenter: Ling Xia
Session: Poster Display session 2
Resources:
Abstract
3982 - Parameters of local cellular immunity in metastatic gastric cancer
Presenter: Aleksandr Sagakyants
Session: Poster Display session 2
Resources:
Abstract
5102 - Germline pathogenic mutations in Chinese patients with gastric cancer identified by next-generation sequencing (NGS)
Presenter: Xiaotian Zhang
Session: Poster Display session 2
Resources:
Abstract
5012 - Inhibition of the PI3K pathway in HER2-positive gastric cancer
Presenter: Sinead Toomey
Session: Poster Display session 2
Resources:
Abstract
4803 - Investigation on gastric cancer susceptibility genes in Chinese early-onset diffuse gastric cancer
Presenter: Yi Feng
Session: Poster Display session 2
Resources:
Abstract
4778 - A correlation analysis between survival rate and the characteristic gene of gastric cancer based on bioinformatics analysis
Presenter: Yi-wen Zhang
Session: Poster Display session 2
Resources:
Abstract
4805 - Phase I study of apatinib combined with POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)
Presenter: Rongbo LIN
Session: Poster Display session 2
Resources:
Abstract
3248 - Second-line palliative systemic treatment for synchronous metastatic esophagogastric cancer: a population-based study
Presenter: Willemieke Dijksterhuis
Session: Poster Display session 2
Resources:
Abstract